Developer docs
API playgroundTry for free, no card

Search company profiles

Javelin Pharmaceuticals

Full company profile

uuid000bsz9

Namestring
Javelin Pharmaceuticals
Legal namestring
Javelin Pharmaceuticals
Company typeenum
Private
Founded yearint
1998
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
specialty pharmaceuticals, pharmaceutical research, drug development, pharmaceutical commercialization, therapeutic products
Industry1 code
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Javelin Pharmaceuticals, Inc. is a specialty pharmaceutical company that engages in the research, development, and commercialization of pharmaceutical products. Founded in 1998 and headquartered in Cambridge, Massachusetts, the company operates with 11-50 employees and has historically raised institutional venture funding to support its pharmaceutical R&D operations. The company's public-facing web presence currently functions as a content site with categories covering medicine, pharmaceuticals, diseases, erectile dysfunction, bruxism, and side effects.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Javelin Pharmaceuticals is a WordPress-based content/news website focused on pharmaceutical news, health topics, and medicine information. The site publishes editorial articles, reviews, and informational content about various pharmaceutical products, health conditions, and treatments including erectile dysfunction, malaria, obesity, antibiotics (Chloramphenicol, Cefadroxil, Ceftin, Bactrim), steroids (Dianabol, Clenbuterol), and other health topics. The site operates as a blog platform rather than a product company with proprietary software offerings.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Peers10 records
1Verywell Health
TypeDirect peer
Description

Verywell Health publishes medically reviewed consumer content on medications, diseases, and wellness, overlapping with Javelin's pharma and disease-content categories.

2GoodRx
TypeEmerging player
Description

GoodRx blends drug-pricing tools with consumer health and medication content; comparable to Javelin's pharma-content positioning while extending into pricing/savings functionality Javelin does not offer.

TypeDirect peer
Description

Healthline operates a consumer health content platform with deep coverage of pharmaceuticals, diseases, and treatment information, closely matching Javelin's stated editorial categories.

TypeDirect peer
Description

Everyday Health publishes condition- and medication-focused content across multiple therapeutic categories, directly comparable to Javelin's cross-category pharma/health publishing.

5Drugs.com
TypeDirect peer
Description

Drugs.com is a pharmaceutical information resource covering drug monographs, side effects, and conditions — a direct functional comparator to Javelin's pharmaceuticals, medicine, and side-effects categories.

TypeBroad incumbent
Description

MedlinePlus, run by the U.S. National Library of Medicine, offers authoritative consumer drug, disease, and treatment information at scale — a much larger, institutionally backed comparator to Javelin's content footprint.

TypeDirect peer
Description

RxList provides detailed drug monographs, pill identifiers, and disease information for consumers and clinicians, mirroring Javelin's pharmaceutical/medicine content focus.

TypeBroad incumbent
Description

Mayo Clinic publishes consumer-friendly information on diseases, drugs, and treatments alongside its clinical practice, giving Javelin a comparable informational category at a vastly broader institutional scale.

TypeBroad incumbent
Description

Cleveland Clinic's Health Essentials is an institutionally backed health-information site covering drugs, diseases, and treatments, comparable in editorial scope to Javelin's content categories.

10WebMD
TypeDirect peer
Description

WebMD is a large-scale consumer health-information publisher covering pharmaceuticals, diseases, treatments, and side effects — directly comparable to Javelin Pharmaceuticals' health/medicine/pharma content positioning.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

No data
Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Javelin Pharmaceuticals

Specialty Pharmaceuticalsjavelinpharmaceuticals.com

Javelin Pharmaceuticals firmographics

Firmographics
Name
Javelin Pharmaceuticals
Legal name
Javelin Pharmaceuticals
Website
https://javelinpharmaceuticals.com
Company type
Private
Founded year
1998
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Javelin Pharmaceuticals industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Specialty pharmaceuticals
  • Pharmaceutical research
  • Drug development
  • Pharmaceutical commercialization
  • Therapeutic products

Where Javelin Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Markets served

Javelin Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing

Marketing channels2 records

Javelin Pharmaceuticals product offering

Product offering

Core offering

Javelin Pharmaceuticals, Inc. is a specialty pharmaceutical company that engages in the research, development, and commercialization of pharmaceutical products. Founded in 1998 and headquartered in Cambridge, Massachusetts, the company operates with 11-50 employees and has historically raised institutional venture funding to support its pharmaceutical R&D operations. The company's public-facing web presence currently functions as a content site with categories covering medicine, pharmaceuticals, diseases, erectile dysfunction, bruxism, and side effects.

Product overview

Javelin Pharmaceuticals is a WordPress-based content/news website focused on pharmaceutical news, health topics, and medicine information. The site publishes editorial articles, reviews, and informational content about various pharmaceutical products, health conditions, and treatments including erectile dysfunction, malaria, obesity, antibiotics (Chloramphenicol, Cefadroxil, Ceftin, Bactrim), steroids (Dianabol, Clenbuterol), and other health topics. The site operates as a blog platform rather than a product company with proprietary software offerings.

Differentiator

Problem solved

Functional benefit

Javelin Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Javelin Pharmaceuticals partnerships and signals

Strategic signal

Recent moves3 records

Javelin Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Verywell Health: Verywell Health publishes medically reviewed consumer content on medications, diseases, and wellness, overlapping with Javelin's pharma and disease-content categories.
  • Healthline Media: Healthline operates a consumer health content platform with deep coverage of pharmaceuticals, diseases, and treatment information, closely matching Javelin's stated editorial categories.
  • Everyday Health Group: Everyday Health publishes condition- and medication-focused content across multiple therapeutic categories, directly comparable to Javelin's cross-category pharma/health publishing.
  • Drugs.com: Drugs.com is a pharmaceutical information resource covering drug monographs, side effects, and conditions — a direct functional comparator to Javelin's pharmaceuticals, medicine, and side-effects categories.
  • RxList: RxList provides detailed drug monographs, pill identifiers, and disease information for consumers and clinicians, mirroring Javelin's pharmaceutical/medicine content focus.
  • WebMD: WebMD is a large-scale consumer health-information publisher covering pharmaceuticals, diseases, treatments, and side effects — directly comparable to Javelin Pharmaceuticals' health/medicine/pharma content positioning.

Emerging players

  • GoodRx: GoodRx blends drug-pricing tools with consumer health and medication content; comparable to Javelin's pharma-content positioning while extending into pricing/savings functionality Javelin does not offer.

Broad incumbents

  • MedlinePlus: MedlinePlus, run by the U.S. National Library of Medicine, offers authoritative consumer drug, disease, and treatment information at scale — a much larger, institutionally backed comparator to Javelin's content footprint.
  • Mayo Clinic (Patient Care & Health Information): Mayo Clinic publishes consumer-friendly information on diseases, drugs, and treatments alongside its clinical practice, giving Javelin a comparable informational category at a vastly broader institutional scale.
  • Cleveland Clinic Health Essentials: Cleveland Clinic's Health Essentials is an institutionally backed health-information site covering drugs, diseases, and treatments, comparable in editorial scope to Javelin's content categories.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat1 record

Key risks5 records

Key highlights4 records

Customer concentration

Javelin Pharmaceuticals social profiles

Digital presence

Javelin Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Javelin Pharmaceuticals leadership team

Management profile

Number of profiles

Javelin Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Javelin Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Javelin Pharmaceuticals

What does Javelin Pharmaceuticals do?

Javelin Pharmaceuticals, Inc. is a specialty pharmaceutical company that engages in the research, development, and commercialization of pharmaceutical products. Founded in 1998 and headquartered in Cambridge, Massachusetts, the company operates with 11-50 employees and has historically raised institutional venture funding to support its pharmaceutical R&D operations. The company's public-facing web presence currently functions as a content site with categories covering medicine, pharmaceuticals, diseases, erectile dysfunction, bruxism, and side effects.

When was Javelin Pharmaceuticals founded?

Javelin Pharmaceuticals was founded in 1998. It employs 11 to 50 people.

Where is Javelin Pharmaceuticals based?

Javelin Pharmaceuticals is headquartered in Cambridge, United States, in the North America region.

Who are Javelin Pharmaceuticals's main competitors?

Direct peers on record are Verywell Health, Healthline Media, Everyday Health Group, Drugs.com, RxList and WebMD. GoodRx is listed as an emerging player. Broad incumbents are MedlinePlus, Mayo Clinic (Patient Care & Health Information) and Cleveland Clinic Health Essentials.

Does Javelin Pharmaceuticals have an API?

No public API is recorded for Javelin Pharmaceuticals.

What industry is Javelin Pharmaceuticals in?

Javelin Pharmaceuticals's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 5417 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireMyriad Pharmaceuticals Announces Termination of Merger Agreement With Javelin PharmaceuticalsMyriad Pharmaceuticals terminated its merger agreement with Javelin Pharmaceuticals effective April 16, 2010. The company is entitled to $1.5 million in expenses, a $2.9 million termination fee, and full repayment of the $8.5 million loan balance plus interest. Myriad will proceed with its shareholder meeting to vote on a name change to Myrexis.GlobeNewswireMyriad Pharmaceuticals Receives Notice of Javelin's Intent to Terminate Merger AgreementJavelin Pharmaceuticals notified Myriad Pharmaceuticals of its intent to terminate the merger agreement, citing a competing acquisition proposal from Hospira as a superior proposal. Myriad will receive repayment of the $8.5 million loan, accrued interest, and a $2.9 million termination fee. Myriad will continue developing its pipeline, including Azixa and MPC-4326.GlobeNewswireMyriad Pharmaceuticals, Inc. Sets Date for Special Stockholder Meeting to Approve Merger with Javelin Pharmaceuticals, Inc.Myriad Pharmaceuticals set April 22, 2010 for a special stockholder meeting to vote on its merger with Javelin Pharmaceuticals, with the record date March 8, 2010. The merger is expected to close shortly after, subject to Javelin's stockholder approval. Javelin's lead product Dyloject has an FDA PDUFA date of October 3, 2010.GlobeNewswireMyriad Pharmaceuticals Reports Second Quarter FY' 2010 Financial ResultsMyriad Pharmaceuticals reported Q2 FY2010 results for the quarter ended December 31, 2009, with an operating loss of $14.8 million and net loss of $14.8 million. The company ended the quarter with $168.7 million in cash and entered a definitive merger with Javelin Pharmaceuticals on December 18, 2009.GlobeNewswireMyriad Pharmaceuticals to Present at BIO CEO & Investor Conference on February 8thMyriad Pharmaceuticals CEO Adrian Hobden will present at the BIO CEO & Investor Conference on February 8th in New York, with Javelin CEO Martin Driscoll joining. The presentation covers the proposed all-stock acquisition of Javelin, expected to close in Q1-Q2 2010.GlobeNewswireFDA Accepts Javelin Pharmaceuticals' Submission and Files New Drug Application for Dyloject(TM)The FDA accepted Javelin Pharmaceuticals' submission and filed a New Drug Application for Dyloject, an injectable NSAID for acute moderate-to-severe postoperative pain. The drug reduced adjunctive opioid use by about 50% in two trials. Myriad Pharmaceuticals plans to acquire Javelin in an all-stock deal expected to close in early 2010.GlobeNewswireMyriad Pharmaceuticals to Acquire Javelin PharmaceuticalsMyriad Pharmaceuticals agreed to acquire Javelin Pharmaceuticals, adding Dyloject, an injectable NSAID for postoperative pain, to its portfolio. The deal, expected to close in Q1 2010, gives Javelin shareholders up to 45% ownership if Dyloject is FDA-approved by June 2010. Dyloject's NDA was submitted on December 2, 2009.